field trip stock

Instrument Name Field Trip Health Ltd Instrument Symbol (FTRPF) Instrument Exchange OTC US

• 3M 3-Months
• 6M 6-Months

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024 .

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab) .

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.

We've detected unusual activity from your computer network

To continue, please click the box below to let us know you're not a robot.

Why did this happen?

Please make sure your browser supports JavaScript and cookies and that you are not blocking them from loading. For more information you can review our Terms of Service and Cookie Policy .

For inquiries related to this message please contact our support team and provide the reference ID below.

English (USA)

English (UK)

English (Canada)

English (India)

Deutsch (Deutschland)

Deutsch (Österreich)

Deutsch (Schweiz)

Français (France)

Français (Suisse)

Nederlands (Nederland)

Nederlands (België)

• Top Capitalization
• United States
• North America
• Middle East
• Sector Research
• Earnings Calendar
• Equities Analysis
• Most popular
• AMD (ADVANCED MICRO DEVICES)
• NIPPON ACTIVE VALUE FUND PLC
• TESLA, INC.
• INTERNATIONAL CONSOLIDATED AIRLINES GROUP, S.A.
• MICROSOFT CORPORATION
• Index Analysis
• Indexes News
• EURO STOXX 50
• Currency Cross Rate
• Currency Converter
• Forex Analysis
• Currencies News
• Precious metals
• Agriculture
• Industrial Metals
• Livestock and Cattle
• CRUDE OIL (WTI)
• CRUDE OIL (BRENT)

• Developed Nations
• Emerging Countries
• South America
• Analyst Reco.
• Capital Markets Transactions
• New Contracts
• Profit Warnings
• Appointments
• Press Releases
• Security Transactions
• Earnings reports
• New markets
• New products
• Corporate strategies
• Legal risks
• Share buybacks
• Mergers and acquisitions
• Call Transcripts
• Currency / Forex
• Commodities
• Cryptocurrencies
• Interest Rates
• Asset Management
• Climate and ESG
• Cybersecurity
• Geopolitics
• Central Banks
• Private Equity
• Business Leaders
• All our articles
• Most Read News
• All Analysis
• Satirical Cartoon
• Today's Editorial
• Crypto Recap
• Behind the numbers
• All our investments
• Asia, Pacific
• Virtual Portfolios
• USA Portfolio
• European Portfolio
• Asian Portfolio
• My previous session
• My most visited
• Yield stocks
• Trend-Following Stocks
• Growth stocks at reasonable prices
• Dividend Aristocrats
• Multibaggers
• Israeli innovation
• The Golden Age of Video Games
• Gold and Silver
• Unusual volumes
• New Historical Highs
• New Historical Lows
• Top Fundamentals
• Sales growth
• Earnings Growth
• Profitability
• Rankings Valuation
• Enterprise value
• Top Consensus
• Analyst Opinion
• Target price
• Estimates Revisions
• Top ranking ESG
• Environment
• Visibility Ranking
• Stock Screener Home
• 3D Printing
• Let's all cycle!
• The genomic revolution
• Oversold stocks
• Overbought stocks
• Close to resistance
• Close to support
• Accumulation Phases
• Most volatile stocks
• Top Investor Rating
• Top Trading Rating
• Top Dividends
• Low valuations
• All my stocks
• Stock Screener
• Stock Screener PRO
• Portfolio Creator
• Event Screener
• Dynamic Chart
• Economic Calendar
• Our subscriptions
• Our Stock Picks
• Thematic Investment Lists

Field Trip Health & Wellness Ltd.

Ca31656q1046, healthcare facilities & services, stella mso, inc. acquired u.s. assets of field trip health & wellness ltd., latest news about field trip health & wellness ltd., chart field trip health & wellness ltd..

Company Profile

Sector other healthcare facilities & services.

• Stock Market
• News Field Trip Health & Wellness Ltd.
• Stella MSO, Inc. acquired U.S. Assets of Field Trip Health & Wellness Ltd.

• Today's news
• Reviews and deals
• Climate change
• 2024 election
• Fall allergies
• Health news
• Mental health
• Sexual health
• Family health
• So mini ways
• Unapologetically
• Buying guides

Entertainment

• How to Watch
• My Portfolio
• Latest News
• Stock Market
• Premium News
• Biden Economy
• EV Deep Dive
• Stocks: Most Actives
• Stocks: Gainers
• Stocks: Losers
• Trending Tickers
• World Indices
• US Treasury Bonds
• Top Mutual Funds
• Highest Open Interest
• Highest Implied Volatility
• Stock Comparison
• Advanced Charts
• Currency Converter
• Basic Materials
• Communication Services
• Consumer Cyclical
• Consumer Defensive
• Financial Services
• Industrials
• Real Estate
• Mutual Funds
• Credit cards
• Balance Transfer Cards
• Cash-back Cards
• Rewards Cards
• Travel Cards
• Personal Loans
• Student Loans
• Car Insurance
• Morning Brief
• Market Domination
• Market Domination Overtime
• Opening Bid
• Stocks in Translation
• Lead This Way
• Good Buy or Goodbye?
• Fantasy football
• Pro Pick 'Em
• College Pick 'Em
• Fantasy baseball
• Fantasy hockey
• Fantasy basketball
• Download the app
• Daily fantasy
• Scores and schedules
• GameChannel
• World Baseball Classic
• Premier League
• CONCACAF League
• Champions League
• Motorsports
• Horse racing
• Newsletters

New on Yahoo

• Privacy Dashboard

Yahoo Finance

Reunion neuroscience inc. (formerly field trip health ltd.) reports fiscal first quarter 2023 financial results, completed corporate reorganization on august 11, 2022.

Completed corporate reorganization, separating the Field Trip Discovery and Field Trip Health divisions into two separate companies.

Field Trip Discovery renamed Reunion Neuroscience Inc. (“ Reunion ” or the “ Company ”), and will remain listed on the NASDAQ Stock Market and Toronto Stock Exchange under new ticker symbol “REUN”.

Field Trip Health renamed Field Trip Health & Wellness Ltd. ( “Field Trip H&W ”) and has received listing approval from the Toronto Stock Exchange Venture under new ticker symbol “FTHW”.

First day of trading for both Reunion and Field Trip H&W is August 17, 2022.

On July 21, 2022, announced successful first dosings in the Company’s Phase 1 Clinical Study of its first novel psychedelic molecule, RE104 (formerly FT-104), being conducted in Australia.

At June 30, 2022, the Company had approximately $52.3 million in unrestricted cash, cash equivalents and short-term investments.

TORONTO, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (formerly “Field Trip Health Ltd.”, or the “Company”) (TSX: FTRP, Nasdaq: FTRP), a leader in novel psychedelic drug development, reported fiscal first quarter 2023 results for the three-month period ended June 30, 2022. All results are reported under International Financial Reporting Standards (" IFRS ") and in Canadian dollars, unless otherwise specified.

Corporate Reorganization Update

On August 11, 2022, the Company completed its previously announced corporate reorganization (the “ Spinout Transaction ”), which resulted in the separation of its Field Trip Discovery and Field Trip Health divisions into two independent companies, completed by way of a Plan of Arrangement (the “ Arrangement ”) under the Canadian Business Corporations Act.

Field Trip Discovery was renamed Reunion Neuroscience Inc., and will remain listed on the NASDAQ Stock Market and Toronto Stock Exchange under the ticker symbol “REUN”. Immediately upon closing of the Arrangement, the Company consolidated its shares on a 5:1 basis, which is expected to cure the NASDAQ minimum bid price deficiency previously announced. The Company also received approval from the Toronto Stock Exchange for Field Trip H&W to list on the TSX-V under the ticker symbol “FTHW”. The first day of trading for both companies under their respective new tickers is August 17, 2022.

Upon closing, the Company transferred the entirety of its clinics in Canada, United States and the Netherlands, its botanical research in Jamaica and part of its corporate operations in Canada and United States (the “ Clinic Operations ”) to Field Trip H&W. For more details on the spinout transaction, please refer to the Key Highlights and Recent Developments – Spinout Transaction section of Company’s MD&A, available under the Company’s SEDAR profile at www.sedar.com .

Joseph del Moral, Founder and Chief Executive Officer of Reunion, said, “We are pleased to have successfully completed the split of Field Trip into two distinct companies - Reunion and Field Trip Health & Wellness. As independent companies, each will be laser-focused on executing their own strategic vision and investment priorities, and creating long-term value for their respective shareholders. The future is bright for both businesses and each is excited to continue developing and delivering innovative psychedelic-assisted treatment options.”

Key Highlights and Recent Developments

Reunion Neuroscience

RE104 (formerly FT-104) Reunion is pioneering the advancement of innovative synthetic molecules targeting serotonin 5HT2A receptors, with RE104 its first of such drug candidates under development. The Company is developing RE104 as a potentially fast-acting treatment with durable efficacy for the key indications of postpartum and treatment resistant depression.

In July, the Company announced the first successful dosings in its Phase 1 Clinical Study of RE104, being undertaken at PARC Clinical Research at the Royal Adelaide Hospital in Australia. The study, entitled “A Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Single, Ascending, Subcutaneous Doses of RE104 HCl In Healthy Volunteers”, principally aims to characterize the safety, tolerability, pharmacokinetics and pharmacodynamic effects of RE104 over a range of dosage levels. Subjective measurements being examined will include intensity, duration and feelings produced by the period of acute psychoactivity after administration of RE104. Reunion expects to report results from the study in the calendar fourth quarter of 2022 and is planning to seek FDA guidance on Phase 2 studies planned for 2023.

During the quarter, the Company was granted a patent for claims related to RE104 entitled, “Tryptamine Prodrugs”. The patent provides exclusive rights to Reunion until 2040 for the composition of matter, formulations, methods of use and methods of manufacture for a family of hemi-ester compounds of hydroxytryptamines, including Isoprocin.

RE200 (formerly FT-200 Group) During the quarter, Reunion continued to progress research and development of its RE200 molecule group, strengthening its IP portfolio while working to determine the optimal lead candidate for preclinical development. The Company has filed two provisional patents with the USPTO relating to the RE200 family to protect the compositions, as well as potential formulations and uses of the molecules.

Dr. Nathan Bryson, Chief Scientific Officer, Reunion, said, “Reunion is proud to be leading the way in developing innovative psychedelic therapeutic solutions, entering our next chapter as a standalone company with an exciting drug discovery pipeline. Our first molecule under development, RE104, has the potential to reduce the treatment burden of psychedelic therapies and provide a safe, fast, and effective treatment option for underserved patients suffering from treatment-resistant and postpartum depression. The achievement of first successful dosings in July in our Phase 1 Clinical Study was a key milestone in our development of RE104 and we are expecting to report study results at the end of the year.”

Field Trip Health & Wellness

During the quarter, the Company launched its ‘Field Trip at Home™ Powered by Nue Life’ platform, which provides patients with access to guided ketamine treatments from the comfort of their home, as an alternative to in-clinic care. With Field Trip at Home™ Field Trip H&W will be able to provide more convenient and accessible treatment options outside of the clinic setting.

Ronan Levy, Chief Executive Officer and Director of Field Trip H&W, commented, “Field Trip Health & Wellness will continue innovating psychedelic-assisted services to drive the best therapeutic outcomes for people, building on our recognized brand and strong reputation as the world’s leading standalone psychedelic-assisted therapy business. With a best-in-class team, we are delivering revenue growth quarter-over-quarter, streamlining our operations and increasing customer reach, leveraging the lessons gained from our three years of operating experience. Moving forward as a standalone business, we will have a dedicated strategic vision and greater flexibility to participate in emerging opportunities in the psychedelic industry.”

Financial Highlights

Selected Consolidated Financial Information

The following table sets forth selected financial information derived from the Company’s unaudited condensed financial statements for the fiscal first quarter 2023 ended June 30, 2022, prepared in accordance with IAS 34 in a manner consistent with the Company’s annual audited financial statements. The following information should be read in conjunction with the financial statements and management’s discussion and analysis, which are available on the Company’s website at www.fieldtriphealth.com and under the Company’s SEDAR profile at www.sedar.com .

Basis of Presentation

The Clinic Operations (or Field Trip H&W) assets and liabilities are classified and presented separately as current items held for transfer related to the spinout in the statement of financial position and are measured at their carrying amount. Clinic Operations are excluded from the results of continuing operations and are presented as a single amount as a net loss after tax from Clinic Operations in the statement of profit or loss.

FIELD TRIP HEALTH LTD

STATEMENTS OF LOSS AND COMPREHENSIVE LOSS

_______________ 1 Assets held for transfer related to spinout of Clinic Operations includes cash and cash equivalents of $4,128,462

Continuing Operations (Reunion) Net loss for the fiscal first quarter 2023 of $5.2 million was primarily due to total operating costs of $5.0 million. This compares with a net loss of $3.4 million in the fiscal first quarter of 2022. The increase in net loss from the prior year primarily reflects the Company’s focus on investing in RE104 which recently began its Phase 1 clinical trial, as well as increased public company costs.

As of June 30, 2022, the Company had unrestricted cash, cash equivalents and short-term investments of $52.3 million, including $4.1 million held at the Clinic Operations.

Clinic Operations (Field Trip H&W)

Over the first fiscal quarter, Field Trip H&W continued to deliver innovative psychedelic-assisted therapies across its 12 operating clinics, achieving revenues of $1.8 million. This represents an increase of 6% over the prior quarter and 110% over the comparative first fiscal quarter of 2022. Revenue growth was driven by the addition of 6 clinics and a volume increase in patient visits.

Net loss for the clinics during the first fiscal quarter 2023 was $8.2 million compared with a $9.1 million loss in the same period of the prior fiscal year. This decrease was primarily due to increased revenue and a more favorable foreign exchange rate, partly offset by the increase in operating costs associated with operating 12 clinics during the quarter, compared to six clinics in the comparative quarter of the prior fiscal year. During the quarter, Field Trip H&W incurred $3.4 million in non-recurring costs: $2.4 million in general and administration expense related to the Spinout Transaction and $1.0 million in occupancy costs related to an impairment write-off of fixed assets arising from the deferral on future clinic openings.

Conference Call

The Company will conduct a conference call and webcast to discuss its results the following morning, Tuesday, August 16, 2022, at 8:30 a.m. ET. To access the call, please dial 1-877-407-9716 (within the U.S.) or 1-201-493-6779 (outside the U.S.) and provide conference ID 13731900. A live webcast of the conference call can be accessed via the Events and Presentations section of the Investor Relations website here .

For those unable to attend the live call, a telephonic replay will be available until 11:59 p.m. ET on Tuesday, August 23, 2022. To access the replay dial 1-844-512-2921 (within the U.S.) or 1-412-317-6671 (outside the U.S.) and provide conference ID 13731900. The webcast will be archived and available in the Events and Presentations section of the Investor Relations website approximately one hour after the conclusion of the live call.

About Reunion Neuroscience Inc., (formerly, Field Trip Health Ltd.)

Reunion is a leader in novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The Company’s lead asset, RE-104 (previously known as FT-104), is a proprietary, novel psychedelic drug being developed for post-partum and treatment resistant depression as a potential fast-acting antidepressant with durable efficacy. Reunion is also developing the FT-200 series, which includes compounds with potential for more selective serotonin receptor activity with reduced psychoactivity for potential use in more chronic treatment paradigms and indications.

About Field Trip Health & Wellness Ltd.

Field Trip Health & Wellness Ltd. is a global leader in psychedelic therapies. With health centres across North America and Europe, along with the digital and technological tools that will enable massive scale, we help people in need with a simple, evidence-based way to heal and heighten engagement with the world.

Learn more at  https://www.meetfieldtrip.com ,  https://www.fieldtriphealth.com and  https://www.fieldtriphealth.nl .

Cautionary Note Regarding Forward-Looking Information 

This release includes forward-looking information (within the meaning of Canadian securities laws and within the meaning of the United States Private Securities Litigation Reform Act of 1995) regarding Field Trip and its business. Often but not always, forward-looking information can be identified by the use of words such as "expect", "intends", "anticipated", "believes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would" or "will" be taken, occur or be achieved. Such statements are based on the current expectations and views of future events of the management of Field Trip and are based on assumptions and subject to risks and uncertainties. Although the management of Field Trip believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the companies, including the timing, completion and potential outcomes of the Spinout Transaction, the funds available to Field Trip and the use of such funds, the ability of Field Trip to operate its clinics, the construction and commencement of construction of additional clinics, the development, patentability and viability of RE104 and the RE200 Group, the ability of Field Trip to complete an investigational new drug application and obtain regulatory approvals, as required, prior to initiating clinical trials for RE104 and molecules within the RE200 Group, the ability of Field Trip to meet eligibility requirements for clinical testing and through to more complex clinical trials, the ability of Field Trip to obtain regulatory approvals prior to each clinical trial and the ability of Field Trip to generate patient member growth, interest in the training program, interest in the various treatment programs by therapists and patients, the ability of management to sustain and continue optimization of its clinical operations, the timing and results of its research and development programs, approval of phase 1 human trials, if any, the risk that future clinical studies may not proceed as expected or may produce unfavorable results, the opening of additional clinics, the COVID-19 epidemic, the medical clinic industry, market conditions, economic factors, management's ability to manage and to operate the business and the equity markets generally. Although Field Trip has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Field Trip does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. Additional information relating to Field Trip, including its Annual Information Form, can be located on the SEDAR website at www.sedar.com and on the EDGAR section of the SEC’s website at www.sec.gov .

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities.

Neither the Toronto Stock Exchange, nor its Regulation Services Provider, have approved the contents of this release or accept responsibility for the adequacy or accuracy of this release.

Reunion Neuroscience: Joseph del Moral [email protected]

Field Trip Health & Wellness: Ronan Levy [email protected]

Investor contacts: Phil Carlson / Sophia Bashford KCSA Strategic Communications [email protected] / [email protected]

Media contacts: McKenna Miller / Nick Opich KCSA Strategic Communications [email protected] / [email protected]

SOURCE Reunion Neuroscience Inc.

Our Locations

Cutting edge care for emotional trauma and mental health challenges.

Our protocols pair in-office medical treatments for mental health with virtual integration therapy to bring dramatic healing in the window of transformation following treatment. 

Today only!

Try a month of our new Hybrid Program FREE . If you're suffering, let this be the beginning of your journey.

In-person Program

Accelerate your healing.

Our immersive in-person ketamine programs are the fastest track to help you reach deep breakthroughs and heal the root of your pain.

Hybrid Program

Start your path to lasting change.

Our holistic, hybrid journey blends ketamine, therapy, meditation, and wellness support in a flexible program that you can complete in-clinic or from the comfort of your home.

Stellate ganglion block

Dual Sympathetic Reset

Field Trip will soon be offering Stella's Dual Sympathetic Reset (DSR) protocol, an advanced Stellate Ganglion Block (SGB) treatment, at its NY and DC locations. This treatment has been shown to relieve symptoms of anxiety, depression, and PTSD/PTSI.

TRANSCRANIAL MAGNETIC STIMULATION (TMS)

FDA-approved treatment for depression.

Biological treatment for depression that’s rooted in brain science. Shown to provide relief for symptoms of major depression disorder through magnetic pulses that regulate activity in the prefrontal cortex.

Self-Guided Program

Explore your inner-self.

Our Field Trip app guides you in connecting with yourself and transcending consciousness, through music, meditations, and tools, created by leaders in mindfulness and psychedelics.

Stay Connected.

Sign up for our email newsletter where we share the latest news, education, events, and research in the psychedelic space.

• TripAdvisor-stock
• News for TripAdvisor

TRIP Stock Earnings: TripAdvisor Beats EPS, Beats Revenue for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips

TripAdvisor (NASDAQ: TRIP ) just reported results for the first quarter of 2024.

• TripAdvisor reported earnings per share of 12 cents. This was above the analyst estimate for EPS of 2 cents.
• The company reported revenue of $395.00 million.
• This was 0.04% better than the analyst estimate for revenue of $394.83 million.

InvestorPlace Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at [email protected].

More From InvestorPlace

• The #1 AI Investment Might Be This Company You’ve Never Heard Of
• Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In.
• It doesn’t matter if you have $500 or $5 million. Do this now.

The post TRIP Stock Earnings: TripAdvisor Beats EPS, Beats Revenue for Q1 2024 appeared first on InvestorPlace .

TripAdvisor News MORE

Related stocks.

Tripadvisor stock sinks as panel rules out sale for now

• Medium Text

Sign up here.

Reporting by Kannaki Deka in Bengaluru; Editing by Shilpi Majumdar

Our Standards: The Thomson Reuters Trust Principles. New Tab , opens new tab

Markets Chevron

Global stocks rally, Europe at record highs, dollar gains

A rally in global equity markets lifted stocks in Europe to record highs on Friday amid strong corporate earnings and hopes central bank interest rate cuts are near, while the dollar edged higher despite signs of slowing U.S. economic growth.

• Stock Market Overview
• Market Momentum
• Market Performance
• Top 100 Stocks
• Today's Price Surprises
• New Highs & Lows
• Economic Overview
• Earnings Within 7 Days
• Earnings & Dividends
• Stock Screener
• Today's Top Stock Pick
• All Top Stock Picks
• Percent Change
• Price Change
• Range Change
• Gap Up & Gap Down
• Five Day Gainers
• Pre-Market Trading
• Post-Market Trading
• Volume Leaders
• Price Volume Leaders
• Volume Advances
• Trading Liquidity
• Market Indices
• S&P Indices
• S&P Sectors
• Dow Jones Indices
• Nasdaq Indices
• Russell Indices
• Volatility Indices
• Commodities Indices
• US Sectors Indices
• World Indices
• New Recommendations
• Top Stocks to Own
• Top Signal Strength
• Top Signal Direction
• Stock Signal Upgrades
• Stock Market Sectors
• Major Markets Heat Map
• Industry Rankings
• Industry Heat Map
• Industry Performance
• Stocks by Grouping
• Options Market Overview
• Unusual Options Activity
• IV Rank and IV Percentile
• Most Active Options
• Unusual Options Volume
• Highest Implied Volatility
• %Change in Volatility
• Options Volume Leaders
• Change in Open Interest
• %Chg in Open Interest
• Upcoming Earnings
• Options Strategy Indexes
• Options Price History
• Options Flow
• Options Calculator
• Options Time & Sales
• Options Screener
• Long Call Screener
• Long Put Screener
• Covered Calls
• Married Put
• Collar Spread
• Bull Call Debit Spreads
• Bear Call Credit Spreads
• Bear Put Debit Spreads
• Bull Put Credit Spreads
• Long Call Calendar
• Long Put Calendar
• Short Straddle
• Long Straddle
• Short Strangle
• Long Strangle
• Long Call Butterfly
• Short Call Butterfly
• Long Put Butterfly
• Short Put Butterfly
• Long Iron Butterfly
• Short Iron Butterfly
• Short Iron Condor
• Long Iron Condor
• Long Call Condor
• Long Put Condor
• Short Call Condor
• Short Put Condor
• ETF Market Overview
• Popular ETFs
• Top 100 ETFs
• Top Dividend ETFs
• ETF Screener
• Top ETFs to Own
• ETFs Signal Upgrades
• Performance
• Funds Screener
• Futures Market Overview
• Long Term Trends
• Highs & Lows
• Futures Market Map
• Performance Leaders
• Most Active Futures
• Prices by Exchange
• Commodities Prices
• Mini & Micro Futures
• Trading Guide
• Historical Performance
• Commitment of Traders
• Legacy Report
• Disaggregated Report
• Financial TFF Report
• Contract Specifications
• Futures Expirations
• First Notice Dates
• Options Expirations
• Economic Calendar
• Cash Markets Overview
• Corn Indexes
• Soybean Indexes
• Yield Forecast Indexes
• Euro Futures Overview
• Power Futures
• Carbon Futures
• European Trading Guide
• Forex Market Overview
• Forex Market Map
• Currency Converter
• Crypto Market Overview
• Market Capitalizations
• Bitcoin Futures
• Popular Cross Rates
• Australian Dollar
• British Pound
• Canadian Dollar
• Japanese Yen
• Swiss Franc
• Metals Rates
• All Forex Markets
• Popular Coins
• Bitcoin-Cash
• Today’s Investing Ideas
• Top Performing Stocks
• Top Trending Tickers
• Barchart Screeners
• Insider Trading Activity
• Politician Insider Trading
• Chart of the Day
• Top Stock Pick
• Futures Trading Guide
• Biotechnology Stocks
• Blockchain Stocks
• Bullish Moving Averages
• Candlestick Patterns
• Cannabis Stocks
• Cathie Wood Stocks
• Clean Energy Stocks
• Cybersecurity Stocks
• Dividend Stocks
• eMACD Buy Signals
• Gold Stocks
• Hot Penny Stocks
• Power Infrastucture
• REIT Stocks
• SPAC Stocks
• Top Stocks Under $10
• TTM Squeeze
• Warren Buffett Stocks
• World Markets
• Markets Today
• Barchart News
• Contributors
• Alan Brugler
• Andrew Hecht
• Angie Setzer
• Darin Newsom
• Gavin McMaster
• Jim Van Meerten
• Josh Enomoto
• Oleksandr Pylypenko
• Rich Asplund
• Rick Orford
• All Authors
• All Commodities
• Food & Beverage
• All Financials
• Interest Rates
• Stock Market
• Top Stories
• All Press Releases
• My Watchlist
• My Portfolio
• Investor Portfolio (BETA)
• Convert Your Portfolios
• Symbol Notes
• Alert Center
• Alert Templates
• Custom Views
• Chart Templates
• Compare Stocks
• Daily Prices Download
• Historical Data Download
• Watchlist Emails
• Portfolio Emails
• Investor Portfolio Emails
• Screener Emails
• End-of-Day My Charts
• End-of-Day Reports
• Organize Watchlists
• Organize Portfolios
• Organize Investor Portfolios
• Organize Screeners
• Organize My Charts
• Site Preferences
• Author Followings
• Upcoming Webinars
• Archived Webinars
• Popular Webinars
• Market on Close
• Market on Close Archive
• Site Education
• Free Newsletters
• Technical Indicators
• Barchart Trading Signals
• Time & Sales Conditions
• Barchart Special Symbols
• Barchart Data Fields
• Barchart Premier
• Barchart Plus
• Membership Comparison
• Barchart for Excel
• Create Free Account
• Price Overview
• Performance Report
• Interactive Chart
• Snapshot Chart
• Barchart Opinion
• Trading Strategies
• Top Trade Alerts
• Technical Analysis
• Trader's Cheat Sheet
• Price History
• Historical Data
• News & Headlines
• Key Statistics
• Stock Comparison
• Insider Trades
• Earnings Estimates
• Analyst Ratings
• Financial Summary
• Income Statement
• Balance Sheet

Field Trip Health Ltd (FTRP.TO)

Fundamentals.

• Market Capitalization, $K 63,386
• Shares Outstanding, K 11,630
• Annual Sales, $ 4,860 K
• Annual Income, $ -54,691 K
• 60-Month Beta N/A
• Price/Sales 12.95
• Price/Cash Flow N/A
• Price/Book 0.95
• Price/Earnings ttm N/A
• Earnings Per Share ttm -4.75
• Most Recent Earnings $-1.25 on N/A
• Latest Earnings Date 08/15/22
• Annual Dividend & Yield N/A (N/A)
• Most Recent Dividend N/A on N/A

Analyst Rating / Earnings Estimates

Current rating, earnings estimates - current qtr 06/30/22.

• Average Estimate -0.20
• Number of Estimates 2
• High Estimate -0.19
• Low Estimate -0.20
• Prior Year -0.20
• Growth Rate Est. (year over year) unch

Price Performance

Most recent stories.

Plans to release financial results for its fiscal 2023 first quarter for the three-month period ended ...

– Field Trip Health & Wellness Ltd. to list on the TSX Venture Exchange, with first day of trading expected to occur on or about August 17, 2022....

Palm Beach, FL – July 27, 2022 – For years, ketamine was known for its use as an anesthetic or as a recreational drug. Its ability to provide quick and safe sedation saved many lives during the Vietnam...

/PRNewswire/ -- For years, ketamine was known for its use as an anesthetic or as a recreational drug. Its ability to provide quick and safe sedation saved many...

Announced today the first successful dosings in the Phase 1 Clinical Study entitled “A Double-Blind, ...

- First Dosings completed in Australia- Provides Update on Pending Spin-Out and Renaming to Reunion Neurosciences- Announces 5:1 Share Consolidation Ratio ...

Completed strategic review and announced intention to separate the Field Trip Discovery and Field Trip Health divisions into two independent public...

- Closing of arrangement subject to regulatory approvals, including conditional listing approval by the TSX Venture Exchange.- Closing of the arrangement...

Approves spin-out of clinics business to Field Trip Health & Wellness Ltd., pending final court approval and additional customary closing conditions...

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Key turning points, want to use this as your default charts setting, switch the market flag, want streaming chart updates, need more chart options, free barchart webinar.